- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01699282
Benefits of a Comprehensive Patient Education on Oral Anticoagulant Compared to Conventional Hospital Education (EDUCA)
Benefits of a Comprehensive Patient Education on Oral Anticoagulant Compared to Conventional Hospital Education.
To meet the wishes of the Ministry of Health, the division of Cardiology University Hospital of Clermont Ferrand, combining the cardiology and cardiac surgery department, has developed since January 2009, a therapeutic education to use oral anticoagulants, in collaboration with the functional rehabilitation center Durtol. All patients under VKA, are formed by nurses. The purpose of this local study, in cardiac surgery department, is to evaluate the therapeutic impact of two methods of comprehensive education, one conventional and performed by nurses service, less elaborate, relying solely on the book Information from The National Security Agency of Medicines and Health Products, the other based on more detailed documents created by a multidisciplinary group. Various studies show that the effect of therapeutic education is observed only during the first six months and then disappears.
This study is the first French study evaluating the impact of a comprehensive education to oral anticoagulation according to the latest recommendations of the National Security Agency of Medicines and Health Products and the French National Health Authority.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To meet the wishes of the Ministry of Health, the division of Cardiology University Hospital of Clermont Ferrand, combining the cardiology and cardiac surgery department, has developed since January 2009, a therapeutic education to use oral anticoagulants, in collaboration with the functional rehabilitation center Durtol. All patients under VKA, are formed by nurses. The purpose of this local study, in cardiac surgery department, is to evaluate the therapeutic impact of two methods of comprehensive education, one conventional and performed by nurses service, less elaborate, relying solely on the book Information from The National Security Agency of Medicines and Health Products, the other based on more detailed documents created by a multidisciplinary group. Various studies show that the effect of therapeutic education is observed only during the first six months and then disappears.
This study is the first French study evaluating the impact of a comprehensive education to oral anticoagulation according to the latest recommendations of the National Security Agency of Medicines and Health Products and the French National Health Authority.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Clermont-Ferrand, France, 63003
- Recruiting
- CHU de Clermont-Ferrand
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults, male or female, over 18 years
- After cardiac surgery
- Requiring an oral anticoagulant in the long term (> 12 months)
- Accepting the principle of extended follow-up
- Voluntary Consent, written and signed by patients
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: control group
|
Group thorough VKA education V.S. control group (conventional hospital education)
|
|
Experimental: Group thorough VKA (antivitamin K)education
|
Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
knowledge test on anticoagulant treatment
Time Frame: after 12 months
|
after 12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHU-0121
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Surgery
-
Tribhuvan University Teaching Hospital, Institute...CompletedCardiac Surgery | Cardiac Surgery Requiring Cardiopulmonary BypassNepal
-
University of Sao Paulo General HospitalInstituto Dante Pazzanese de Cardiologia; Irmandade da Santa Casa de Misericordia... and other collaboratorsRecruitingCardiac Surgery | ERAS | Digital Health | Cardiac Surgery-CABGBrazil
-
Nationwide Children's HospitalCompleted
-
Asan Medical CenterCompleted
-
Shanghai Zhongshan HospitalRecruitingCardiac Surgery | Cardiac OutputChina
-
Sheba Medical CenterTerminatedDisorder; Heart, Functional, Postoperative, Cardiac Surgery | Heart; Dysfunction Postoperative, Cardiac SurgeryIsrael
-
Universitätsklinikum Hamburg-EppendorfCompletedSerratus Anterior Plane Block | Minimal Invasive Cardiac Surgery | Minimal Invasive Cardiac Surgery Mitral Valve SurgeryGermany
-
Nantes University HospitalCompletedCardiac Surgery Requiring Cardiopulmonary Bypass | Cardiac Surgery Under Extra Corporeal CirculationFrance
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); Population Health Research Institute and other collaboratorsActive, not recruitingSurgery (Cardiac) | Surgery (Major Vascular)Canada, United Kingdom
-
Baylor Research InstituteChiesi USA, Inc.CompletedSurgery | Cardiac Surgery | Surgery--Complications | Percutaneous Coronary InterventionUnited States
Clinical Trials on VKA (antivitamin K) education
-
Attikon HospitalHellenic Cardiology SocietyCompletedCoronary Artery Disease | Atrial FibrillationGreece
-
Janssen Scientific Affairs, LLCBayerCompletedAtrial FibrillationUnited States, France, United Kingdom, Belgium, Germany
-
BayerJanssen Research & Development, LLCCompletedNonvalvular Atrial FibrillationUnited States
-
BayerJanssen Research & Development, LLCCompletedAtrial FibrillationUnited States
-
BayerJanssen Research & Development, LLCCompletedAtrial FibrillationBelgium, France, Spain, China, Italy, United States, Canada, South Africa, Portugal, Singapore, Germany, Greece, Netherlands, United Kingdom, Brazil, Denmark, Finland
-
Bristol-Myers SquibbCompleted
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceTerminatedRenal InsufficiencyFrance
-
SanofiCompletedDeep Vein ThrombosisUnited States
-
Population Health Research InstituteBayer; University of Cape TownCompletedRheumatic Heart DiseaseBotswana, Philippines, Zimbabwe, India, China, Egypt, Ethiopia, Uganda, Brazil, South Africa, Cameroon, Tanzania, Kenya, Zambia, Kazakhstan, Kyrgyzstan, Malawi, Mexico, Mozambique, Nepal, Nigeria, Pakistan, Paraguay, Rwanda, Sudan
-
BayerJanssen Research & Development, LLCCompletedTreatment of Venous Thromboembolism in Cancer PatientsSweden